TTIPFThiogenesis Therapeutics Corp.

About Thiogenesis Therapeutics Corp. (TTIPF)

Thiogenesis Therapeutics Corp. (TTIPF) is a Biotechnology company headquartered in Toronto, ON, Canada whose shares trade over-the-counter on the OTCQX tier.

Thiogenesis Therapeutics, Corp., is a clinical-stage biopharmaceutical company operating through its wholly owned subsidiary based in San Diego, CA. Thiogenesis is developing sulfur-containing prodrugs that act as precursors to previously approved thiol compounds, with the potential to treat serious pediatric diseases with unmet medical needs. Prodrugs are drugs that contain previously approved active ingredients and are modified so that they only become active when metabolized. For regulatory purposes prodrugs can use existing third-party safety data in regulatory submissions in the streamlined 505 (b)(2) regulatory pathway in the US, and its equivalent hybrid system in Europe, to proceed into human efficacy trials with regulatory clearance. Prodrugs may enhance the profile of the active ingredient to increase its bioavailability and reduce side effects. The Company's initial target indications include Mitochondrial Encephalopathy Lactic Acidosis and Stroke ("MELAS"), Leigh's syndrome, Rett syndrome and pediatric MASH.

Products and services

N/A

TTIPF key facts

Ticker symbol

TTIPF

Market tier

OTCQX

Sector

Healthcare

Industry

Biotechnology

Headquarters

Toronto, ON, Canada

Country of incorporation

CA

Year of incorporation

2018

Employees

1

Estimated market cap

$20.38M (as of May 14, 2025)

Shares outstanding

46,306,890

Reporting standard

International Reporting: TSX Venture Exchange

Audit status

Audited

Fiscal year end

12/31

Latest filing

Interim Financial Report (Mar 31, 2022)

Thiogenesis Therapeutics Corp. leadership

• Patrice P Rioux — CEO
• Brook Riggins — CFO, Corporate Secretary
• Victoria Bantz — Counsel
• Sandra Hall — Consultant

Explore more: Biotechnology stocks · Healthcare sector · OTCQX stocks · OTC stocks starting with T